

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Corrigendum

Corrigendum to “Bevacizumab in the first-line treatment of metastatic breast cancer” [EJC Suppl. 6(6) (2008) 21–28]

David Cameron*

Department of Oncology, University of Leeds, Leeds, United Kingdom

The author regrets that there is an error on page 22 of the article mentioned above.

The E2100 study is described as a multicentre, randomised, phase III study comparing the combination of bevacizumab with and without paclitaxel as first-line therapy in patients with advanced breast cancer not previously treated with che-

motherapy. The correct description of the study is a multicentre, randomised, phase III study comparing the combination of paclitaxel with and without bevacizumab as first-line therapy in patients with advanced breast cancer not previously treated with chemotherapy.

DOI of original article: [10.1016/S1359-6349\(08\)70289-1](https://doi.org/10.1016/S1359-6349(08)70289-1)

* Tel.: +44 113 343 8033; fax: +44 113 343 2242.

E-mail address: d.cameron@ncrn.org.

0959-8049/\$ - see front matter © 2008 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2008.07.025